{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T09:21:12Z","timestamp":1790328072003,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,10,6]],"date-time":"2016-10-06T00:00:00Z","timestamp":1475712000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["DARU J Pharm Sci"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s40199-016-0163-8","type":"journal-article","created":{"date-parts":[[2016,10,5]],"date-time":"2016-10-05T23:50:09Z","timestamp":1475711409000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Opportunities and obstacles to the development of nanopharmaceuticals for human use"],"prefix":"10.1186","volume":"24","author":[{"given":"Nasser","family":"Nassiri Koopaei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Abdollahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,6]]},"reference":[{"key":"163_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-10-0791-0","volume-title":"Pharmaceutical Nanotechnology: Fundamentals and Practical Applications","author":"C Demetzos","year":"2016","unstructured":"Demetzos C. Pharmaceutical Nanotechnology: Fundamentals and Practical Applications. Singapore: Springer; 2016."},{"key":"163_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-2140-5","volume-title":"Nanomedicine: Principles and Perspectives","author":"Y Ge","year":"2014","unstructured":"Ge Y, Li S, Wang S, Moore R. Nanomedicine: Principles and Perspectives. New York: Springer; 2014."},{"issue":"3","key":"163_CR3","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.bbrc.2015.10.136","volume":"468","author":"EH Chang","year":"2015","unstructured":"Chang EH, Harford JB, Eaton MAW, Boisseau PM, Dube A, Hayeshi R, Swai H, Lee DS. Nanomedicine: past, present and future\u2013a global perspective. Bioch Bioph Res Co. 2015;468(3):511\u20137.","journal-title":"Bioch Bioph Res Co"},{"issue":"1","key":"163_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1560-8115-20-1","volume":"20","author":"A Pourmand","year":"2012","unstructured":"Pourmand A, Abdollahi M. Current opinion on nanotoxicology. DARU. 2012;20(1):1.","journal-title":"DARU"},{"key":"163_CR5","doi-asserted-by":"publisher","first-page":"4357","DOI":"10.2147\/IJN.S46900","volume":"9","author":"V Weissig","year":"2014","unstructured":"Weissig V, Pettinger TK, Murdock N. Nanopharmaceuticals (part 1): products on the market. Int J Nanomed. 2014;9:4357.","journal-title":"Int J Nanomed."},{"key":"163_CR6","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.2147\/IJN.S65526","volume":"10","author":"V Weissig","year":"2015","unstructured":"Weissig V, Guzman-Villanueva D. Nanopharmaceuticals (part 2): products in the pipeline. Int J Nanomed. 2015;10:1245.","journal-title":"Int J Nanomed."},{"key":"163_CR7","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1039\/9781782622536-00290","volume-title":"Nanomedicines: design, delivery and detection","author":"R Bawa","year":"2016","unstructured":"Bawa R, Barenholz Y, Owen A. The challenge of regulating nanomedicine: Key issues, in nanomedicines. In: Braddock M, editor. Nanomedicines: design, delivery and detection. Cambridge: Royal Society of Chemistry; 2016. p. 290\u2013314."},{"key":"163_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-62703-140-0","volume-title":"Nanotechnology for nucleic acid delivery","author":"M Ogris","year":"2013","unstructured":"Ogris M, Oupicky D. Nanotechnology for nucleic acid delivery. New York: Humana Press; 2013."},{"issue":"1","key":"163_CR9","first-page":"1","volume":"20","author":"H Bahadar","year":"2016","unstructured":"Bahadar H, Maqbool F, Niaz K, Abdollahi M. Toxicity of nanoparticles and an overview of current experimental models. Iran Biomed J. 2016;20(1):1.","journal-title":"Iran Biomed J"},{"key":"163_CR10","volume-title":"Handbook of Clinical Nanomedicine From Bench to Bedside","author":"R Bawa","year":"2015","unstructured":"Bawa R. Handbook of Clinical Nanomedicine From Bench to Bedside. Boca Raton: Pan Stanford Publishing; 2015."},{"issue":"10","key":"163_CR11","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1021\/ar200019c","volume":"44","author":"T Lammers","year":"2011","unstructured":"Lammers T, Aime S, Hennink WE, Storm G, Kiessling F. Theranostic nanomedicine. Accounts Chem Res. 2011;44(10):1029\u201338.","journal-title":"Accounts Chem Res"},{"issue":"4","key":"163_CR12","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2174\/156720112801323125","volume":"9","author":"H Abdelkader","year":"2012","unstructured":"Abdelkader H, Alany RG. Controlled and continuous release ocular drug delivery systems: pros and cons. Curr Drug Deliv. 2012;9(4):421\u201330.","journal-title":"Curr Drug Deliv"},{"issue":"13","key":"163_CR13","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.addr.2012.08.005","volume":"64","author":"XQ Zhang","year":"2012","unstructured":"Zhang XQ, Xu X, Bertrand N, Pridgen E, Swami A, Farokhzad OC. Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine. Adv Drug Deliv Rev. 2012;64(13):1363\u201384.","journal-title":"Adv Drug Deliv Rev"},{"issue":"6","key":"163_CR14","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.addr.2009.03.006","volume":"61","author":"BS Zolnik","year":"2009","unstructured":"Zolnik BS, Sadrieh N. Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs. Adv Drug Deliver Rev. 2009;61(6):422\u20137.","journal-title":"Adv Drug Deliver Rev"},{"issue":"1","key":"163_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2008-2231-21-14","volume":"21","author":"S Mostafalou","year":"2013","unstructured":"Mostafalou S, Mohammadi H, Ramazani A, Abdollahi M. Different biokinetics of nanomedicines linking to their toxicity; an overview. DARU. 2013;21(1):1.","journal-title":"DARU"},{"issue":"4","key":"163_CR16","doi-asserted-by":"publisher","first-page":"218","DOI":"10.2174\/1570163813666160114093140","volume":"12","author":"S Saeidnia","year":"2015","unstructured":"Saeidnia S, Manayi A, Abdollahi M. From in vitro Experiments to in vivo and Clinical Studies; Pros and Cons. Curr Drug Discov Technol. 2015;12(4):218\u201324.","journal-title":"Curr Drug Discov Technol"},{"key":"163_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.taap.2016.02.014","volume":"299","author":"A Shvedova","year":"2016","unstructured":"Shvedova A, Pietroiusti A, Kagan V. Nanotoxicology ten years later: lights and shadows. Toxicol Appl Pharm. 2016;299:1\u20132.","journal-title":"Toxicol Appl Pharm."},{"issue":"6","key":"163_CR18","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3923\/ijp.2012.594.595","volume":"8","author":"SV Shetab-Boushehri","year":"2012","unstructured":"Shetab-Boushehri SV, Abdollahi M. Current concerns on the validity of in vitro models that use transformed neoplastic cells in pharmacology and toxicology. Int J Pharmacol. 2012;8(6):594\u20135.","journal-title":"Int J Pharmacol"},{"issue":"4","key":"163_CR19","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/etc.3039","volume":"35","author":"S Berkner","year":"2015","unstructured":"Berkner S, Schwirn K, Voelker D. Nanopharmaceuticals: Tiny challenges for the environmental risk assessment of pharmaceuticals. Environ Toxicol Chem. 2015;35(4):780\u20137.","journal-title":"Environ Toxicol Chem"},{"key":"163_CR20","unstructured":"http:\/\/www.fda.gov\/RegulatoryInformation\/Guidances\/ucm257698.htm\n                    \n                  . Accessed 13 Sept 2016."},{"key":"163_CR21","unstructured":"http:\/\/www.fda.gov\/ScienceResearch\/SpecialTopics\/Nanotechnology\/ucm301114.htm\n                    \n                  . Accessed 13 Sept 2016."},{"key":"163_CR22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jconrel.2014.05.036","volume":"187","author":"CM Dawidczyk","year":"2014","unstructured":"Dawidczyk CM, Kim C, Park JH, Russell LM, Lee KH, Pomper MG, Searson PC. State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. J Control Release. 2014;187:133\u201344.","journal-title":"J Control Release."},{"issue":"2","key":"163_CR23","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s00216-010-3972-5","volume":"398","author":"CL Haynes","year":"2010","unstructured":"Haynes CL. The emerging field of nanotoxicology. Anal Bioanal Chem. 2010;398(2):587\u20138.","journal-title":"Anal Bioanal Chem"},{"key":"163_CR24","doi-asserted-by":"publisher","DOI":"10.1201\/b16562","volume-title":"Nanotoxicology: progress toward nanomedicine","author":"NA Monteiro-Riviere","year":"2014","unstructured":"Monteiro-Riviere NA, Tran CL. Nanotoxicology: progress toward nanomedicine. Boca Raton: CRC press; 2014."},{"issue":"2","key":"163_CR25","first-page":"10","volume":"5","author":"M Srikumaran","year":"2008","unstructured":"Srikumaran M. Nanopharmaceuticals patenting issues and FDA regulatory challenges. Sci Tech Lawyer. 2008;5(2):10.","journal-title":"Sci Tech Lawyer"},{"issue":"12","key":"163_CR26","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1038\/nbt1171","volume":"23","author":"CC Lee","year":"2005","unstructured":"Lee CC, MacKay JA, Fr\u00e9chet JMJ, Szoka FC. Designing dendrimers for biological applications. Nat biotechnol. 2005;23(12):1517\u201326.","journal-title":"Nat biotechnol"},{"issue":"10","key":"163_CR27","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1080\/17460441.2016.1217196","volume":"11","author":"M Safavi","year":"2016","unstructured":"Safavi M, Sabourian R, Abdollahi M. The development of biomarkers to reduce attrition rate in drug discovery focused on oncology and central nervous system. Expert Opin Drug Discov. 2016;11(10):939\u201356.","journal-title":"Expert Opin Drug Discov"},{"issue":"1","key":"163_CR28","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.nano.2015.08.006","volume":"12","author":"L Bregoli","year":"2016","unstructured":"Bregoli L, Movia D, Gavigan-Imedio JD, Lysaght J, Reynolds J, Prina-Mello A. Nanomedicine applied to translational oncology: a future perspective on cancer treatment. Nanomedicine. 2016;12(1):81\u2013103.","journal-title":"Nanomedicine"},{"key":"163_CR29","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4172\/2157-7439.1000334","volume":"6","author":"H Lloyd-Hughes","year":"2015","unstructured":"Lloyd-Hughes H, Shiatis AE, Pabari A, Mosahebi A, Seifalian A. Current and future nanotechnology applications in the management of melanoma: a review. J Nanomed Nanotechnol. 2015;6:6.","journal-title":"J Nanomed Nanotechnol."},{"issue":"2","key":"163_CR30","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3390\/cosmetics2020177","volume":"2","author":"A Landriscina","year":"2015","unstructured":"Landriscina A, Rosen J, Friedman AJ. Nanotechnology, inflammation and the skin barrier: innovative approaches for skin health and cosmesis. Cosmetics. 2015;2(2):177\u201386.","journal-title":"Cosmetics"},{"issue":"1","key":"163_CR31","first-page":"3","volume":"1","author":"M Kumar","year":"2015","unstructured":"Kumar M, Verma D, Yadav R. Nanomedicine: future prospective in disease diagnosis and preventions. World J Clin Pharmacol Microbiol Toxicol. 2015;1(1):3\u20138.","journal-title":"World J Clin Pharmacol Microbiol Toxicol"},{"key":"163_CR32","doi-asserted-by":"publisher","unstructured":"Anderson D, Sydor MJ, Fletcher P, Holian A. Nanotechnology: The Risks and Benefits for Medical Diagnosis and Treatment. J Nanomed Nanotechnol. 2016; doi:\n                    10.4172\/2157-7439.1000e143","DOI":"10.4172\/2157-7439.1000e143"},{"issue":"2","key":"163_CR33","doi-asserted-by":"publisher","first-page":"50","DOI":"10.7196\/sajbl.432","volume":"8","author":"J Gardner","year":"2015","unstructured":"Gardner J. Nanotechnology in medicine and healthcare: Possibilities, progress and problems. SAJBL. 2015;8(2):50\u20133.","journal-title":"SAJBL"},{"key":"163_CR34","doi-asserted-by":"publisher","unstructured":"Pottier A, Borghi E, Levy L. The future of nanosized radiation enhancers. Br J Radiol. 2015; doi:\n                    10.1259\/bjr.20150171","DOI":"10.1259\/bjr.20150171"},{"issue":"1","key":"163_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2217\/nnm.15.152","volume":"11","author":"IK Herrmann","year":"2016","unstructured":"Herrmann IK, R\u00f6sslein M. Personalized medicine: the enabling role of nanotechnology. Nanomedicine. 2016;11(1):1\u20133.","journal-title":"Nanomedicine"}],"updated-by":[{"DOI":"10.1186\/s40199-016-0164-7","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2016,11,10]],"date-time":"2016-11-10T00:00:00Z","timestamp":1478736000000}}],"container-title":["DARU Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40199-016-0163-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40199-016-0163-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40199-016-0163-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T20:53:22Z","timestamp":1568667202000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1186\/s40199-016-0163-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,6]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["163"],"URL":"https:\/\/doi.org\/10.1186\/s40199-016-0163-8","relation":{"erratum":[{"id-type":"doi","id":"10.1186\/s40199-016-0164-7","asserted-by":"object"}]},"ISSN":["2008-2231"],"issn-type":[{"value":"2008-2231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,6]]},"assertion":[{"value":"24 August 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"23"}}